News Sentiment

NVCT sentiment intelligence

Nuvectis Pharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.14 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+4.3% over one week, +38.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction 4.3% Price confirming higher
Trend fit Trend active 38.5% over four weeks
Fair value 125.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 25
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 7
TradingView 4
simplywall.st 4
MT Newswires 3
Moomoo 2
Investing.com 2
Cantech Letter 1

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 11
Deals and strategy 3
Analyst action 2
Macro sensitivity 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Cantech Letter Direct company coverage

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Nuvectis Pharma (NASDAQ: NVCT) has secured worldwide rights outside China for NXP100, a once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), following a licensing deal with Haisco Pharmaceutical Group. NXP100 showed strong positive Phase 3 data, outperforming th

Tone
Positive 72/100
Event
Deals and strategy
Published
14 Jul 2026 15:43
Source
Cantech Letter
FinanzNachrichten.de Direct company coverage

Wall Street Wire: StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Nuvectis Pharma (NASDAQ: NVCT) recently acquired worldwide rights outside China for NXP100, a promising once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), following a licensing deal with Haisco Pharmaceutical Group. This acquisition, supported by strong Phase

Tone
Positive 72/100
Event
Deals and strategy
Published
14 Jul 2026 14:42
Source
FinanzNachrichten.de
Stock Traders Daily Direct company coverage

How (NVCT) Movements Inform Risk Allocation Models

This article analyzes Nuvectis Pharma Inc. (NASDAQ: NVCT) using AI models to provide insights into its market movements and inform risk allocation. It highlights weak near-term sentiment but strong mid and long-term signals, offering three distinct trading strategies tailored to

Tone
Positive 65/100
Event
Market update
Published
13 Jul 2026 20:41
Source
Stock Traders Daily
TradingView Direct company coverage

The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush

Nuvectis Pharma recently acquired worldwide rights outside China for NXP100, a once-daily pill for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. This acquisition, along with an oncology drug NXP200, signifies the company's shift from a single-drug oncology foc

Tone
Positive 85/100
Event
Deals and strategy
Published
09 Jul 2026 19:11
Source
TradingView
Stocktwits Direct company coverage

Nuvectis Pharma Inc (NVCT) News, Articles, Events & Latest Updates

This article provides recent news and updates for Nuvectis Pharma Inc (NVCT), including analyst ratings and price targets suggesting significant upside potential. It highlights the company's recent earnings beat, increased holdings by Iridian Asset Management, and a stock jump fo

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 08:11
Source
Stocktwits
Simply Wall Street Direct company coverage

Nuvectis Pharma (Nasdaq:NVCT) - Stock Analysis

Nuvectis Pharma (NVCT) is a clinical-stage biopharmaceutical company focused on oncology, currently developing precision medicines NXP900 and NXP800. The company has a market capitalization of US$605.3m, but faces significant risks including revenue less than US$1m, unprofitabili

Tone
Positive 63/100
Event
Earnings
Published
07 Jul 2026 19:42
Source
Simply Wall Street
Moomoo Direct company coverage

Nuvectis Pharma Price Target Raised to $33.00/Share From $20.00 by Roth Capital

Roth Capital has increased its price target for Nuvectis Pharma (NVCT) to $33.00 per share, up from the previous $20.00. This revision suggests a significantly more optimistic outlook on the company's future stock performance.

Tone
Positive 70/100
Event
Analyst action
Published
06 Jul 2026 18:41
Source
Moomoo
scanx.trade Direct company coverage

Roth Capital raises Nuvectis target to $33

Roth Capital analyst Jonathan Aschoff maintained a Buy rating on Nuvectis Pharma and increased the price target from $20 to $33. This adjustment follows Nuvectis's announcement of a $100 million public offering of 5,000,000 shares at $20.00 each, with the proceeds intended to adv

Tone
Positive 71/100
Event
Analyst action
Published
06 Jul 2026 16:11
Source
scanx.trade
Stock Titan Direct company coverage

Nuvectis Pharma (NVCT) CEO Ron Bentsur buys $250,000 in shares

Nuvectis Pharma's Chairman and CEO, Ron Bentsur, purchased 12,500 shares of common stock at $20.00 per share, totaling $250,000. This open-market purchase was part of a public offering announced on June 29, 2026. Following this transaction, Bentsur directly owns 3,688,424 shares

Tone
Positive 71/100
Event
Market update
Published
02 Jul 2026 05:40
Source
Stock Titan
The Globe and Mail Direct company coverage

Nuvectis Pharma Announces Major Public Equity Offering

Nuvectis Pharma (NVCT) announced a firm-commitment public offering of 5,000,000 common shares at $20.00 each through Cantor Fitzgerald, with an option for underwriters to purchase an additional 750,000 shares. This offering is expected to raise approximately $93 million in net pr

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 05:10
Source
The Globe and Mail
Investing.com Direct company coverage

Nuvectis Pharma 10% owner Mosseri buys $916k in shares

Marlio Charles Mosseri, a 10% owner of Nuvectis Pharma (NASDAQ:NVCT), acquired 50,000 shares worth $916,000 on June 30, 2026, at an average price of $18.32 per share. This insider purchase follows a significant stock decline and a $100 million public offering at a 30% discount. D

Tone
Positive 59/100
Event
Market update
Published
02 Jul 2026 04:40
Source
Investing.com
GuruFocus Direct company coverage

Insider Buying: Ron Bentsur Acquires Additional Shares of Nuvectis Pharma Inc (NVCT)

Ron Bentsur, Chairman & CEO of Nuvectis Pharma Inc (NVCT), recently purchased 12,500 shares of the company, bringing his total ownership to 3,688,424 shares. This transaction is part of a trend of insider buying at Nuvectis Pharma, with six insider buys and no sells over the last

Tone
Positive 72/100
Event
Market update
Published
01 Jul 2026 20:10
Source
GuruFocus
Stock Titan Direct company coverage

[Form 4] Nuvectis Pharma, Inc. Insider Trading Activity

Emerald Hill Ventures SARL SPF, an entity beneficially owned by 10% owner Charles Mosseri Marlio, purchased 50,000 shares of Nuvectis Pharma, Inc. (NVCT) common stock at a weighted average price of $18.32 per share. This open-market transaction increased their indirect holdings t

Tone
Positive 74/100
Event
Market update
Published
01 Jul 2026 18:10
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Nuvectis Pharma Inc For: 1 July By Investing.com

This article reports on a Form 4 filing for Nuvectis Pharma Inc (NVCT) for transactions made on July 1st. It also includes current financial market data, indices, commodity prices, and other related financial news, with Nuvectis Pharma's stock showing a 6.14% increase.

Tone
Neutral 50/100
Event
Macro sensitivity
Published
01 Jul 2026 18:10
Source
Investing.com Canada
AllSci Direct company coverage

Nuvectis Raises $100M for Oncology Pivot

Nuvectis Pharma, Inc. has raised $100 million through an underwritten public offering to fund the development of three clinical-stage programs acquired from Haisco Pharmaceutical Group. This financing supports a strategic shift to include complement-mediated rare diseases and onc

Tone
Positive 72/100
Event
Market update
Published
01 Jul 2026 14:11
Source
AllSci
Stock Titan Direct company coverage

Nuvectis Pharma (NASDAQ: NVCT) cuts and suspends $5M ATM share sales

Nuvectis Pharma (NVCT) has reduced the available amount for sales under its "at-the-market" equity program with Leerink Partners to $5 million and concurrently suspended the use of the current Sales Agreement Prospectus. The company will not sell shares under this agreement until

Tone
Negative 37/100
Event
Market update
Published
01 Jul 2026 06:41
Source
Stock Titan
Investing News Network Direct company coverage

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Nuvectis Pharma, Inc. (Nasdaq: NVCT) announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $20.00 per share, aiming for gross proceeds of $100 million. The company also granted underwriters a 30-day option to purchase up to an additio

Tone
Positive 70/100
Event
Market update
Published
01 Jul 2026 04:40
Source
Investing News Network
Stock Titan Direct company coverage

Nuvectis Pharma (NASDAQ: NVCT) to raise $100M in stock sale

Nuvectis Pharma announced a firm commitment public offering of 5,000,000 shares of common stock at $20.00 per share, aiming to raise $100 million in gross proceeds. Underwriters have an option to purchase an additional 750,000 shares, potentially increasing net proceeds to $107 m

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 04:09
Source
Stock Titan
TradingView Direct company coverage

Nuvectis Pharma Sets 5M-Share, $20 Offering; ~$93M Net, Cantor Fitzgerald Underwriter

Nuvectis Pharma has entered into an underwriting agreement with Cantor Fitzgerald for a public offering of 5,000,000 shares of common stock at $20.00 per share. The offering is expected to close on July 1, 2026, and generate approximately $93 million in net proceeds, or about $10

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 21:09
Source
TradingView
Moomoo Direct company coverage

Press Release: Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Nuvectis Pharma has announced the pricing of its public offering of 4,000,000 shares of its common stock at $25.00 per share, aiming to raise $100 million before deductions. The offering includes a 30-day option for underwriters to purchase an additional 600,000 shares. The commo

Tone
Positive 71/100
Event
Market update
Published
30 Jun 2026 18:11
Source
Moomoo
Quiver Quantitative Direct company coverage

Nuvectis Pharma Prices $100 Million Underwritten Public Offering of Common Stock

Nuvectis Pharma has announced the pricing of a public offering of 5 million shares of common stock at $20.00 per share, aiming to raise $100 million. The funds are intended to advance the development of its product candidates NXP100, NXP200, and NXP900, alongside hiring and gener

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 14:40
Source
Quiver Quantitative
Kavout | AI Direct company coverage

Nuvectis Pharma's $100 Million Offering: Dilution at a Discount Amidst Pipeline Hopes

Nuvectis Pharma recently completed a $100 million public offering at $20.00 per share, significantly diluting existing shareholders but providing critical funding for its oncology and immune complement pipeline. Despite the discount, the stock trades higher at $28.53, reflecting

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 08:40
Source
Kavout | AI
Market source Direct company coverage

Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)

Nuvectis Pharma's shares dropped 25% in premarket trading after the company priced a $100 million public offering at $20.00 per share, a 30% discount from the previous day's closing price of $28.53. The offering involves 5,000,000 shares of common stock, and the underwriters have

Tone
Negative 25/100
Event
Market update
Published
30 Jun 2026 08:36
Source
Market source